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ABSTRACT 
The metabolic syndrome (MetS) is a diagnosis that includes several clinical 
criteria that indicate a higher than normal risk of developing cardiovascular disease. 
Central adiposity is considered a risk factor for the MetS and is also associated with 
increased mortality and morbidity. The use of ultrasonography (US) has made it possible 
to measure the amount of visceral fat (VF) in a cost-effective and non-invasive manner as 
opposed to computed tomography or magnetic resonance imaging. C-reactive protein 
(CRP), an acute phase inflammatory marker, has been associated with increased risk for 
cardiovascular disease and has been shown to have a relationship with VF levels. The 
purpose of the study was to determine the relationship between VF, CRP, and the MetS. 
Visceral fat, CRP, MetS risk factors were evaluated in 34 participants who were over the 
age of 40. An ultrasound scan at the waist was conducted to determine VF levels by 
placing the wand 1 cm to the right of the umbilicus and performing a 10 cm scan towards 
the right hip. Waist circumference was measured at the superior portion of the iliac crest. 
CRP, blood glucose, HDL cholesterol, and triglycerides (TG) were measured using a 
blood analyzer. Pearson’s Correlations were conducted to determine the relationships 
between VF, CRP, and MetS risk factors. All variables were tested with an alpha level of 
p ≤ .05. There were significant positive correlations between CRP and VF (r = .34, p = 
.05) and CRP and TG (r = .50, p < .002). The results indicate the use of US as a cost-
effective, non-invasive method of evaluating potential risk for increased inflammation as 
well as the development of the MetS and may be a viable alternative to traditional 
methods of measuring VF. 
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Chapter 1 
Introduction 
The metabolic syndrome (MetS) is a series of clinical findings that when clustered 
together, increases the risk of developing type 2 diabetes and cardiovascular disease 
(Wilson, D’Agostino, Parise, Sullivan, & Meigs, 2005). Several organizations have 
provided clinical definitions for the diagnosis of the MetS, but the definitions between 
organizations differ (Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004). The 
components of a MetS diagnosis are elevated triglycerides (TG), decreased high density 
lipoprotein cholesterol (HDL-C), hypertension, increased central obesity, and elevated 
fasting glucose levels. These risk factors are all independently related to an increased risk 
for cardiovascular disease, but the presence of the MetS increases the risk exponentially 
more than simply combining the individual risk factors (Ford, 2005; Isomaa et al., 2001; 
Malone et al., 2009). Individuals with the MetS also have an increased risk for 
developing type 2 diabetes (Lorenzo, Okoloise, Williams, Stern, & Haffner, 2003; 
Wilson et al., 2005). There is a smaller, but still significant increase in risk for 
cardiovascular disease and cardiovascular mortality for those with the MetS (Chambers et 
al., 2001; Isomaa et al., 2001; Ridker et al., 2003; Rutter, Meigs, Sullivan, D’Agostino, & 
Wilson, 2004; Wilson et al., 2005). 
Recent data suggests that between 23% - 35% of all adult Americans have the 
MetS and approximately 40% of people over the age 60 have the diagnosis (Malone et 
al., 2009). In November of 2007, the American College of Sports Medicine (ACSM), in 
partnership with the American Heart Association, launched an initiative entitled Exercise 
is Medicine. The purpose of the initiative is for health care providers to include physical 
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activity as a vital sign during check-ups and to include physical activity as an avenue for 
chronic disease prevention and/or treatment. Lakka et al. (2003) concluded that a  
sedentary lifestyle and poor cardiorespiratory fitness led to an increase in risk for being 
diagnosed with the MetS. The researchers found that the least fit participants were nearly 
seven times more likely to have the MetS compared with the most fit participants (Lakka 
et al., 2003). On top of this finding, Lakka et al., (2003) concluded that low levels of 
moderate and vigorous physical activity were associated with the risk factors for the 
MetS as well as other factors related to the MetS such as inflammatory markers.   
The Exercise is Medicine initiative can have a significant economic impact, but is 
dependent on allied health professionals and primary care givers committing to the core 
tenet that exercise can prevent and treat many chronic diseases. In a study done on the 
health care costs of the MetS, researchers compared the annual cost of health care for 
those with or without MetS and also compared those with and without type 2 diabetes 
(Boudreau et al., 2009). The total annual cost of health care is made up of four categories; 
inpatient, primary care, outpatient, and pharmacy. For patients with the MetS, the average 
cost for health care annually was $5,732 versus $3,581 for subjects without the MetS 
(Boudreau et al., 2009). Additionally, the inpatient and pharmacy cost for those with the 
MetS were double the cost of those without. Because there is a much greater risk for 
developing type 2 diabetes in the presence of the MetS, understanding the health care 
costs in patients with or without type 2 diabetes is also important. Those with type 2 
diabetes had a much higher cost annually than those with the MetS at $6,038 (Boudreau 
et al., 2009). Overall, there is a clear link between the MetS and increased health care 
costs including even higher costs for those with the MetS and type 2 diabetes, thereby 
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increasing the need for the most practical and direct method of detecting, preventing, and 
treating the MetS. 
There has been a relationship established between the MetS risk factors and C-
reactive protein (CRP), but it is traditionally been assessed using the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATPIII) definition. The 
relationship between CRP and the MetS as defined by the World Health Organization 
(WHO) is also defined in the literature. In the larger scale, cross-sectional studies 
examining the relationship between CRP and the MetS, a strong correlation has been 
shown establishing a link between CRP and the MetS. Within these studies not all MetS 
risk factors were measured at the time of data collection and some factors were self-
reported by participants (such as blood pressure). These studies also utilized waist 
circumference, waist-to-hip ratio, or BMI to measure central obesity, but none of those 
methods are able to differentiate between subcutaneous and visceral fat compartments. 
This is of significance as visceral fat has been shown to be more metabolically active 
than subcutaneous fat and has also been shown to be a stronger, more reliable predictor of 
future cardiovascular and metabolic disease (Ibrahim, 2009).  
There is a well-documented relationship between obesity and an increased risk for 
metabolic and cardiovascular disease (Hamdy, Porramtikul, & Al-Ozairi, 2006; Ibrahim, 
2009; Porter et al., 2009). Currently, approximately two out of three Americans are 
overweight or obese according to BMI classifications, which has steadily increased over 
the past 30 years (Low, Chew, & Deurenberg-Yap, 2009). Increased BMI creates an 
immediate and significant impact on our health care system costs as the cost per person, 
per year for someone who is overweight or obese ($498 and $1,630 respectively) is 
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significantly higher than a normal weight person’s medical costs (Tsai, Williamson, & 
Glick, 2010). Obesity costs account for approximately 5% of health care spending in the 
United States (Tsai et al., 2010). Several studies suggest that central obesity is more 
strongly associated with increased risks for metabolic and cardiovascular disease when 
compared to total adiposity (Hamdy et al., 2006; Ibrahim, 2009; Liu et al., 2010; Smith et 
al., 2012). Additionally, visceral fat has a stronger correlation to the risk factors for MetS 
than that of subcutaneous fat even after the adjustment for weight (BMI; Liu et al., 2010). 
The gold standards for measuring visceral fat are through computed tomography 
(CT) scans or magnetic resonance imaging (MRI), which are expensive and difficult to 
access for the general population. Recently, ultrasonography has been utilized and 
validated as a method to measure visceral fat levels (Alempijevic et al., 2011; Gong et al., 
2007; Hirooka et al., 2005; Kim et al., 2004; Rolfe et al., 2010; Shojaei et al., 2010; 
Stolk, Meijer, Mali, Grobbee, & Van Der Graaf, 2003; Stolk et al., 2001). The 
relationship between visceral fat measured through ultrasonography have been compared 
to visceral fat using CT (r = 0.82 - 0.86) and MRI (r = 0.77) with strong correlations 
(Gong et al., 2007; Hirooka et al., 2005; Stolk et al., 2003). This comparison between the 
gold standards of measuring visceral fat and ultrasonography lend validity to 
ultrasonography as an alternative, accessible, and inexpensive measurement tool for 
central obesity that is more practical for allied health professionals. Therefore, the use of 
ultrasound to measure visceral fat as a replacement for waist circumference and other 
anthropometric measures of obesity may provide a valid, practical, and cost-effective 
measurement of central obesity in the definition of the MetS.  
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Purpose Statement 
 The primary purpose of this study was to determine the relationship between 
CRP, visceral fat, and the metabolic syndrome (MetS) risk factors.  
Hypotheses 
Ho: There will be no significant correlations between CRP and the MetS risk 
factors. 
Ha: There will be significant, positive correlations between CRP and the 
following MetS risk factors: triglycerides, blood pressure, fasting glucose, and 
visceral fat. 
Ha: There will be a significant, negative correlation between CRP and HDL-C. 
Operational Definitions 
 The Metabolic Syndrome: The clustering of three or more of the following risk 
factors as defined by the National Cholesterol Education Program ATP III: elevated 
triglycerides, hypertension, low levels of high density lipoprotein cholesterol, visceral 
adiposity, and elevated fasting glucose. TG, HDL-C, and fasting glucose were measured 
with a Cholestech LDX Analyzer. Blood pressure was measured using an aneroid 
sphygmomanometer and waist circumference was measured with a Gulick tape measure. 
The specific thresholds for each of the risk factors are as follows (Grundy et al., 2004):  
Elevated TG. Characterized by blood TG levels >150 mg/dl. 
Hypertension. Characterized by systolic blood pressure >130 mmHg and/or 
diastolic blood pressure >85 mmHg. 
 Reduced HDL-C. Characterized by < 40 mg/dl of HDL-C for males and <50 
mg/dl for females.  
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 Elevated waist circumference. Characterized by waist circumference >102 cm for 
males and >88 cm for females. 
 Elevated (impaired) fasting glucose. Characterized by fasting glucose levels 
>110 mg/dl. 
 Body Mass Index: Body mass index (BMI) is the ratio of height to 
weight. The formula used for BMI in this study was weight in kilograms divided 
by height in meters squared. 
Assumptions 
An important aspect of collecting the most accurate blood glucose and cholesterol 
information is for the participant to be fasting for 10-12 hours before testing. It is 
assumed that all participants followed this protocol to produce the most valid results 
possible. 
Delimitations and Limitations 
 The sample population for this study was delimited to older adults. For the 
purpose of this study, those over the age of 40 were considered older adults. Also, the 
sample size was delimited to 50 participants due to issues surrounding cost of equipment 
and limited funding.    
Significance 
 The importance of preventing the onset or the early detection and treatment of the 
MetS is increasing as our population ages, becomes more sedentary, and more obese. 
Currently, the estimates for Americans who have the MetS range from 23% - 35% with 
this number reaching over 40% in those who are over the age of 60 (Malone et al., 2009). 
By determining how CRP relates to the MetS risk factors in a relatively older population 
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(older than 40) as well as exploring the relationship between CRP and visceral fat, allied 
health professionals will gain important insight into potential methods of screening and 
monitoring for MetS risk factors. The use of ultrasonography in the current study is also 
significant because it may eliminate the need to use expensive, inaccessible methods of 
measurement such as MRI or CT scans.  
Overall, the goal of the study was to determine the most practical, cost-effective 
method of identifying the MetS for the purpose of prevention, early detection, and early 
treatment. Allied health professionals, along with primary care givers such as physicians, 
are a crucial link to preventing the onset of chronic diseases such as the MetS, type 2 
diabetes, and cardiovascular disease. In line with the Exercise is Medicine campaign, 
equipping these professionals with the methods to better help their clients will only have 
a favorable effect on the impact of chronic disease on their substantial health care costs.  
 
  
Chapter 2 
Review of Literature 
Introduction  
The purpose of this study was to determine the relationship between CRP, an 
inflammatory marker, and the metabolic syndrome (MetS) risk factors using the NCEP 
ATPIII definition while including visceral fat measurements through ultrasonography. 
This chapter provides a review of the metabolic syndrome, visceral fat, and inflammation 
as well as the interrelationships amongst them.   
The Metabolic Syndrome 
 The metabolic syndrome (MetS) is characterized by a series of clinical findings 
including hypertension, dyslipidemia, impaired glucose sensitivity, and visceral adiposity 
and it is estimated that approximately one in four people in the United States are living 
with the MetS (Wilson et al., 2005). People diagnosed with the MetS are at a higher risk 
for developing type 2 diabetes as well as cardiovascular disease, which has a significant 
economic impact in terms of health care costs. The burden of type 2 diabetes and 
cardiovascular disease on United States health care costs is over $600 billion annually 
(Rice, Cifelli, Pikosky, & Miller, 2011). More specifically, the health care costs for 
individuals with and those without the MetS are substantially different. According to 
Boudreau et al. (2009), health care utilization as well as costs was significantly greater in 
patients with the MetS compared to patients without the MetS. Average annual total costs 
for patients who had the MetS were 1.6 times higher than patients without the MetS 
($5,732 vs. $3,581; Boudreau et al., 2009). Therefore, it is both in the best interest of 
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individuals as well as the population as a whole to determine the most cost-effective, 
practical methods of screening, preventing, and treating the components of the MetS. 
 For the purpose of this study, the most recent definition for MetS provided by the 
NCEP ATPIII was used. There are other commonly used definitions, such as one defined 
by the WHO. The two definitions are described below for the purpose of comparison as 
they are the most commonly used in the MetS literature (Ford et al., 2005). The NCEP 
ATP III definition was chosen for the current study as the WHO standards are difficult to 
measure outside of a hospital or lab setting. The NCEP ATP III criteria are the most 
easily measured and identified and the thresholds for the criteria are less stringent than 
other definitions because having multiple risk factors that are marginal increases the risk 
for cardiovascular disease (Grundy et al., 2004).  
NCEP ATP III MetS definition. The current definition for the MetS in the 
NCEP ATP III is the presence of any three (or more) of the following risk factors: 
elevated TG, hypertension, reduced HDL-C, elevated waist circumference, and elevated 
fasting glucose (Grundy et al., 2004).                        
WHO MetS definition. Defined as insulin resistance as classified by one of the 
following: Type 2 diabetes, impaired fasting glucose, impaired glucose tolerance, or 
those with glucose uptake below the lowest quartile for background population under 
investigation under hyperinsulinemic or euglycemic conditions. Along with insulin 
resistance, at least two of the following have to present as well: antihypertensive 
medication and/or high blood pressure, elevated plasma triglycerides, elevated BMI 
and/or waist to hip ratio, and elevated urinary albumin excretion rate or the 
albumin:creatinine ratio (Grundy et al., 2004).                               
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 The primary risk factors for the MetS have been strongly associated with risk for 
developing type 2 diabetes using both the NCEP ATP III and WHO definitions (Bernard 
et al., 2007; Ford, 2005; Hanson et al., 2002; Lorenzo et al., 2003; Rutter et al., 2004; 
Wilson et al., 2005). Research has shown that several risk factors for type 2 diabetes are 
strongly correlated with each other, which has led to the belief that they arise from 
common factors (Hanson, Imperatore, Bennett, & Knowler, 2002). Obesity, central 
adiposity, hypertension, insulin resistance, hypoalphalipoprotein, and 
hypertriglyceridemia have been described as primary risk factors for type 2 diabetes and 
because these risk factors are often clustered, it has been hypothesized that they stem 
from a limited number of or a single metabolic abnormality (Hanson et al., 2002). Of the 
aforementioned risk factors for type 2 diabetes, the combination of hypertension, insulin 
resistance, dyslipidemia, and obesity fall into the definition for the MetS. Previous 
research has shown that as the number of metabolic syndrome risk factors increases, the 
higher the risk there is for developing type 2 diabetes (Wilson et al., 2005). 
In addition to the individual MetS risk factors being associated with type 2 
diabetes, there is an increased relative risk for developing type 2 diabetes for those with 
the MetS (Ford, 2005; Hanson et al., 2002; Lorenzo et al., 2003; Wilson et al., 2005). 
Throughout the research, there is consensus that there is an increased risk for type 2 
diabetes, but the relative risk values differ. The range of relative risk for type 2 diabetes 
in those who have the MetS is 1.5 to 17.9 (Ford, 2005; Hanson et al., 2002; Lorenzo et 
al., 2003; Wilson et al., 2005). These relative risk values include research studies that 
utilized both the NCEP ATP III definition and the WHO definition for the MetS, which is 
important to note. The range presented is significantly large, but Ford (2005) performed a 
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meta-analysis of studies that evaluated relative risk for type 2 diabetes in those with the 
MetS and concluded that the NCEP definition yielded a collective relative risk of 2.99. 
Much of the difference in relative risk values in the research can be attributed to the 
definition of the MetS being used. Hanson et al. (2002) showed that the relative risk for 
type 2 diabetes using the WHO definition was significantly higher than the relative risk 
using the NCEP ATP III definition within the same population (3.58 & 2.09). This 
difference in relative risk is credited to the fact that the WHO definition for the MetS 
requires impaired fasting glucose plus two additional risk factors whereas the NCEP ATP 
III definition simply requires any three risk factors (Hanson et al., 2002). The fact that the 
NCEP ATP III definition treats all five risk factors equally and does not require impaired 
fasting glucose for diagnosis plays a significant role in relative risk calculations for 
predicting the development of type 2 diabetes compared to the WHO definition. 
Impaired fasting glucose, a primary risk factor for the MetS, is diagnosed when 
fasting blood glucose levels are greater than or equal to 110 mg/dL. The presence of 
impaired fasting glucose very often precedes the onset of type 2 diabetes (Lorenzo et al., 
2003; Wilson et al., 2005). In a study done examining the MetS as a precursor of 
cardiovascular disease and type 2 diabetes, the researchers found that having the MetS is 
a good predictor of developing type 2 diabetes (Wilson et al., 2005). Within the same 
research, an 8-year follow-up study, the researchers found that participants who only had 
one component (impaired fasting glucose) of the MetS were at a much higher risk of 
developing type 2 diabetes when compared to participants who had any one of the other 
four MetS risk factors (Wilson et al., 2005). These results indicate that having impaired 
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fasting glucose is a good predictor of a future type 2 diabetes diagnosis and is an 
independent risk factor of incident type 2 diabetes.  
The relative risk for type 2 diabetes for someone who only displays impaired 
fasting glucose is significantly higher (12.5) than the relative risks for type 2 diabetes for 
those who have elevated TG (2.9), hypertension (2.4), elevated waist circumference (4.1), 
and low HDL-C (2.7; Wilson et al., 2005). These specific results indicate that the 
appearance of the impaired fasting glucose risk factor for MetS has a larger impact on the 
relative risk and prevalence of future type 2 diabetes diagnoses, as the relative risk for 
non-impaired glucose fasting risk factors was three to five times lower (Wilson et al., 
2005).  
For those who had two MetS components with one being impaired fasting 
glucose, the relative risk for type 2 diabetes was two to three times higher than those who 
had two MetS components without having impaired fasting glucose (Wilson et al., 2005). 
Participants who had three MetS components, including impaired fasting glucose, also 
had two to three times higher relative risk for type 2 diabetes (Wilson et al., 2005). 
Interestingly, the relative risk for those with two compared to three MetS components 
(both including impaired fasting glucose) was not significantly different, which is 
important as it may indicate that any level of clustering of risk factors including impaired 
fasting glucose shows a central insulin-resistant pathophysiology. Although participants 
who showed the impaired fasting glucose component of MetS suffered from a higher 
relative risk than those who did not, all participants who had any form of risk factor 
clustering suffered from a higher relative risk.           
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 Individuals who have been diagnosed with the MetS are also at an increased risk 
for developing cardiovascular disease (Chambers et al., 2001; Isomaa et al., 2001; Ridker 
et al., 2003; Rutter et al., 2004; Wilson et al., 2005). The risk factors for the MetS have 
all independently been linked to a greater risk for cardiovascular disease, but the presence 
of MetS increases that risk even further (Ford, 2005; Isomaa et al., 2001; Malone et al., 
2009). The use of differing definitions of the MetS as well as different criteria within 
each definition has led to an inconsistency in the numbers related to the relative risk of 
cardiovascular disease for those with the MetS. In spite of these discrepancies, the 
overwhelming consensus is that being diagnosed with the MetS increases the risk for 
cardiovascular disease as well as cardiovascular mortality (Chambers et al., 2001; Ford, 
2005; Isomaa et al., 2001; Malone et al., 2009; Ridker et al., 2003; Rutter et al., 2004; 
Wilson et al., 2005).  
Isomaa et al. (2001) suggests that the presence of the MetS was related to an 
increase in cardiovascular disease, specifically coronary heart disease, acute myocardial 
infarction, and stroke. The relative risk for coronary heart disease using the WHO 
definition of the MetS was 2.96, whereas the risk for acute myocardial infarction was 
2.63 and the risk for stroke was 2.27 (Isomaa et al., 2001). Using the NCEP ATPIII 
definition of the MetS, it was shown that the relative risk for developing cardiovascular 
disease ranged from 3.40 to 5.64 based on the number of MetS risk factors present (3-5 
risk factors, respectively; Malone et al., 2009). Additionally, it was found that 
dyslipidemia was associated with a higher risk for cardiovascular disease in patients with 
type 2 diabetes and hypertension was associated with a higher risk in patients without 
type 2 diabetes (Isomaa et al., 2001). In addition to being at a higher risk for 
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cardiovascular disease, Isomaa et al. (2001) found that cardiovascular mortality was 
increased in patients with the MetS compared to those without the MetS (12% v. 2%). 
They also identified the combinations of obesity and hypertension and obesity and 
dyslipidemia as the most common risk factor combinations, which are similar to the 
findings of Malone et al., (2009).  
Malone et al. (2009) proposes that the specific combination of risk factor 
clustering is the most important factor for an increased risk of cardiovascular disease. 
Malone et al. (2009) examined the specific combinations of risk factors and determined 
that low HDL-C levels were present in the combinations with the highest relative risks 
and that the combination of impaired fasting glucose, hypertension, and dyslipidemia 
inferred the highest risk for cardiovascular disease of any of the combinations. Also, their 
findings showed that hypertension was the greatest independent contributing risk factor 
for increase in risk for stroke whereas low HDL-C was the greatest contributing risk 
factor for the increase in risk for acute myocardial infarction (Malone et al., 2009). These 
results are significant as low levels of HDL-C was a stronger risk factor than type 2 
diabetes for acute myocardial infarction and stroke, but the clusters of risk factors that 
contributed the most to increased risk of cardiovascular disease included both HDL-C 
and impaired fasting glucose (Malone et al., 2009). 
 Although there are discrepancies in relative risk values for the MetS throughout 
the literature and future risk for cardiovascular disease and mortality due to differing 
definitions, there is a consensus that a relationship exists between the MetS and an 
increased risk for cardiovascular disease and mortality (Chambers et al., 2001; Ford, 
2005; Isomaa et al., 2001; Malone et al., 2009; Ridker et al., 2003; Rutter et al., 2004; 
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Wilson et al., 2005). It also appears that the clustering of MetS risk factors contributes 
more to an increased risk for cardiovascular disease and mortality than the individual 
components of the MetS alone (Malone et al., 2009). Also, the specific clusters of risk 
factors seems to play a significant role in the development of cardiovascular disease, with 
the specific combination of impaired fasting glucose, dyslipidemia, and hypertension 
inferring the highest risk (Malone et al., 2009).  
Inflammation 
 There is a relationship between inflammatory markers, such as CRP, and 
cardiovascular disease in both men and women (McLaughlin et al., 2002; Yudkin, 
Stehouwer, Emeis, & Coppack, 1999). There is inconclusive evidence identifying the 
cause of the inflammation and the exact role that it plays, but there are several hypotheses 
for the etiology of the relationship between inflammation and cardiovascular disease.  
 Several epidemiological studies suggest that a strong relationship exists between 
CRP and the MetS, however, it is not well understood (Frohlich et al., 2000; Kahn et al., 
2006; Ridker et al., 2003; Rutter et al., 2004; Wilson et al., 2005). A prominent theme is 
that adipose tissue and the associated cytokines produced play a strong role. The primary 
inflammatory markers that have been explored in relationship to cardiovascular disease 
and the MetS are CRP, interleukin-6 (Il-6), and tumor necrosis factor alpha (TNFa; 
Frolich et al., 2000). Il-6 and TNFa are both pro-inflammatory cytokines which are 
directly related to levels of CRP, an acute phase inflammatory protein (Hak et al., 1999). 
Adipocytes are the primary producer of TNFa within the human body and have 
paracrine properties (Hak et al., 1999). The production of TNFa by adipose tissue leads to 
the production of Il-6, which has endocrine properties and is a prime regulator of CRP 
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(Hak et al., 1999). According to Yudkin et al. (1999), blood concentrations as well as 
production of Il-6 increases with increased adiposity and approximately 30% of 
circulating Il-6 stems from adipose tissue. In the same study, the researchers identified a 
statistically significant relationship between CRP and both Il-6 and TNFa (Yudkin et al., 
1999). TNFa also inhibits insulin-stimulated glucose uptake in cells and also plays a role 
in decreasing lipoprotein lipase activity, which are important processes in the 
development of several of the MetS risk factors (Frolich et al., 2000). The relationship 
between the pro-inflammatory cytokines that are initiated by adipose tissue and CRP has 
important implications for the development of the MetS.  
 Several studies investigating the relationship between the MetS and CRP have 
suggested that the components of the MetS and the MetS itself are associated with an 
inflammatory response (Frohlich et al., 2000; Kahn et al., 2006; Ridker et al., 2003; 
Rutter et al., 2004). The stratification of CRP levels and the number of MetS risk factors 
showed that there was a positive, statistically significant relationship between the two 
(Frolich et al., 2000; Rutter et al., 2004). Also, researcher has shown that CRP levels 
were higher among women than men in those with and without the MetS (Rutter et al., 
2004).  
Researchers have been unable to identify the cause and effect relationship 
between CRP and the MetS, but a clear relationship between the two has been identified 
(Frohlich et al., 2000; Kahn et al., 2006; Ridker et al., 2003; Rutter et al., 2004; Wilson et 
al., 2005). Additionally, recent research exploring the relationship between CRP and the 
MetS has shown that CRP levels increase as the number of MetS risk factors increases 
(Frolich et al., 2000; Rutter et al., 2004). Also of importance is the fact that the current 
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research on the relationship between CRP and the MetS has been done using laboratory 
testing and analysis for CRP (requiring a blood draw). Researchers in the current study 
were only able to analyze CRP levels through a finger stick and a small amount of blood 
by using the Cholestech LDX Analyzer.  
Visceral Fat  
Adiposity is classified as two different components based on primary storage site, 
visceral fat and subcutaneous fat. Visceral fat is a specific type of adipose tissue that is 
located around internal organs and is also known as intraabdominal fat. Visceral fat 
accounts for 10-20% of total fat in males and 5-8% in females, making it far less 
common than subcutaneous fat (Ibrahim, 2009). It has been shown that visceral fat has a 
stronger correlation to the risk factors for MetS than that of subcutaneous fat and remains 
so even after the adjustment for weight (BMI; Liu et al., 2010). Also, the use of these 
common anthropometric measurements ignores the variability that is present between the 
distribution of fat within ethnic groups as well as males and females. For example, it has 
been shown that African-Americans have higher rates of obesity as defined by BMI than 
European Americans, but have lower amounts of visceral fat (Liu et al., 2010). Similarly, 
Nazare et al. (2012) showed that East Asians had lower BMI values but higher visceral 
fat content than other ethnic groups.  
There are anatomical and structural differences between visceral and 
subcutaneous fat that are crucial to understanding the role they play in the development 
of the MetS. One of the primary anatomical differences between visceral and 
subcutaneous fat is the location of venous blood drainage. Subcutaneous fat has venous 
drainage through systemic veins, which is in contrast to visceral fat venous drainage 
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which occurs via the hepatic portal vein (Ibrahim, 2009). This is significant because the 
portal drainage that occurs with visceral fat provides the liver with immediate access to 
free fatty acids as well as adipokines. Adipokines are responsible for hepatic immune 
mechanisms which produce important inflammatory markers such as CRP (Ibrahim, 
2009).  
The structural differences in visceral fat and subcutaneous fat have a significant 
role in the development of the MetS. In general, adipose tissue is composed of a large 
number of adipocytes as well as a variety of other non-fat cells such as macrophages and 
immune cells (Ibrahim, 2009). A distinguishing difference in structure between visceral 
fat and subcutaneous fat is the size of the adipocytes. The role of adipocytes within 
adipose tissue is to store energy, which is in the form of triglyceride droplets. Research 
has indicated that visceral fat contains a greater number of large adipocytes when 
compared to subcutaneous fat, which contains a greater number of smaller adipocytes 
(Ibrahim, 2009). This is important because when adipocytes get too large, they become 
dysfunctional and are more resistant to insulin itself as well as to the anti-lipolytic effect 
of insulin, which directly affects the development of the MetS (Ibrahim, 2009).  
There have been a number of studies conducted to assess the predictive ability of 
visceral and subcutaneous fat for cardiometabolic diseases (Fox et al., 2007; Liu et al., 
2010; Smith et al., 2012). The research indicates that correlations between visceral and 
subcutaneous fat and the risk factors for MetS were statistically significant (Fox et al., 
2007; Liu et al., 2010; Smith et al., 2012). However, the correlations for visceral fat were 
consistently stronger than the correlations for subcutaneous fat. Additionally, only 
visceral fat correlations remained strong after adjusting for waist circumference and body 
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mass index, which suggests that quantifying visceral fat provides more information than 
anthropometric measurements provide (Fox et al., 2007; Liu et al., 2010). Also, research 
has shown that visceral fat is correlated to future risk for cardiovascular disease (Smith et 
al., 2012). Results from these studies indicate that visceral fat is better correlate to the 
MetS than subcutaneous fat and gives more information regarding MetS risk factors than 
common anthropometric measurements such as body mass index and waist 
circumference. Furthermore, these studies suggest that the relationship between visceral 
fat is stronger and more persistent than measures of subcutaneous fat when assessing 
central obesity.  
 As well as being strongly correlated to the MetS risk factors, visceral fat has also 
been shown to be strongly related to inflammatory markers such as CRP (Forouhi, Sattar, 
& McKeigue, 2001; Khera et al., 2009; Lemieux et al., 2001; Park et al., 2010; Saijo et 
al., 2004). These correlations were found in a variety of populations, including 
Canadians, Europeans, South and East Asians as well as in overweight and obese 
populations (Forouhi et al., 2001; Khera et al., 2009; Lemieux et al., 2001; Park et al., 
2010; Saijo et al., 2004). The relationship between CRP and visceral fat suggests that 
visceral fat is an important contributor to chronic inflammation, especially in those who 
are overweight or obese (Forouhi et al., 2001; Khera et al., 2009; Lemieux et al., 2001; 
Park et al., 2010; Saijo et al., 2004). It is important to note that these correlations between 
the MetS and visceral fat were obtained primarily through the use of CT. There is a lack 
of scientific data that shows the relationship between visceral fat measured through 
ultrasonography and CRP levels.  
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Visceral Fat Measurement 
Body composition methodology and risk identification has traditionally been in 
the form of hydrostatic weighing and more recently air displacement plethysmography. 
However, these forms of measuring body composition fail to account for different fat 
compartments and just report an overall amount or percentage of fat. Octopolar 
bioelectrical impedance devices have the ability to measure fat amounts in different 
regions of the body including the trunk, but fail to differentiate between subcutaneous 
and visceral fat. Similarly, external anthropometric methods of assessing abdominal 
obesity such as waist circumference and waist-to-hip ratio are unable to differentiate the 
fat compartments.  
Both the NCEP ATPIII and the WHO definitions for the MetS utilize the 
following anthropometric measurements to evaluate obesity: BMI, waist-to-hip ratio, and 
waist circumference (Grundy et al., 2004). These anthropometric measurements are 
commonly utilized because of their cost-effectiveness and ease of use, but fail to 
differentiate fat compartments (visceral vs. subcutaneous) or in the case of BMI, fail to 
account for any sort of distribution of fat. Although these measurements are easy to 
administer and are correlated with other measures of central obesity, they fail to 
specifically account for the more harmful and metabolically active visceral fat tissue 
(Taylor et al., 2010). It has been shown that central obesity is more strongly associated 
with increased risks for metabolic and cardiovascular disease when compared to total 
adiposity (Hamdy et al., 2006; Ibrahim, 2009; Liu et al., 2010; Smith et al., 2012). As 
such, estimates of obesity within populations being studied as it relates to the MetS are 
inconsistent and are heavily dependent on the definitions being used. Isomma et al. 
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(2001) showed that obesity defined by waist-to-hip ratio was more common than obesity 
defined by BMI classifications. The differences were not subtle as only 10% of males and 
14% of females were classified as obese using BMI classifications whereas 76% of males 
and 36% of females were classified as obese using waist-to-hip ratio classifications 
within the same population (Isomma et al., 2001). 
Currently, CT is considered one of the gold standards of measuring visceral and 
subcutaneous fat compartments along with MRI techniques. Although these measurement 
methodologies are the most direct way of differentiating the fat compartments, they are 
also extremely expensive, non-portable, and can expose people to harmful radiation. The 
use of ultrasonography to measure visceral and subcutaneous fat compartments may be a 
more practical, cost-effective, and portable method. In addition to these benefits, the use 
of ultrasonography has been shown to be a valid and reproducible method of measuring 
visceral fat (Alempijevic et al., 2011; Gong et al., 2007; Hirooka et al., 2005; Kim et al., 
2004; Rolfe et al., 2010; Shojaei et al., 2010; Stolk et al., 2003; Stolk et al., 2001). The 
use of ultrasonography has also been used in older populations (Rolfe et al., 2010) as well 
as those with chronic disease (Shojaei et al., 2010) to measure visceral fat. Additionally, 
it has been used to estimate risks for cardiovascular and metabolic diseases (Kim et al., 
2004). Stolk et al., (2003) utilized ultrasonography measurements of visceral fat and 
showed that it was a better predictor of the MetS than the commonly used waist 
circumference measurement, which is an important finding that was used for the 
foundation of the current study. Although ultrasonography has been shown to be a valid 
method of measuring visceral fat, it has been validated in settings with clinical grade 
equipment and technicians which can be cost-prohibitive. Recently, an ultrasound 
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machine has been produced for use by allied health professionals. This provides a more 
cost-effective alternative to clinical ultrasound testing and needs to be validated against 
the MetS risk factors. 
Visceral fat is a more metabolically active fat depot (Ibrahim, 2009) and is more 
strongly related to the MetS than subcutaneous fat (Fox et al., 2012; Fox et al., 2007; Liu 
et al., 2010). Therefore, it is essential to differentiate the two fat compartments when 
determining the relationship to the MetS rather than using common anthropometric 
measurements. There is also a relationship between visceral fat and inflammatory 
markers such as CRP, but they have only been established through the use of CT. The use 
of CT and MRI are the gold standards for measuring different fat compartments, but both 
have a high cost and can contribute to radiation exposure. The use of ultrasonography has 
been proposed as a valid, reproducible technique to measure visceral fat in a variety of 
populations and has strong correlations to measurements of visceral fat measured through 
both CT and MRI techniques (Alempijevic et al., 2011; Gong et al., 2007; Hirooka et al., 
2005; Kim et al., 2004; Rolfe et al., 2010; Shojaei et al., 2010; Stolk, Meijer, Mali, 
Grobbee, & Van Der Graaf, 2003; Stolk et al., 2001).  
 
Summary 
 Reviewing the current literature it is apparent that the MetS is a strong risk factor 
associated with elevated health care costs as well as two major lifestyle related diseases 
type 2 diabetes and cardiovascular disease. The syndrome is strongly associated with the 
level of visceral fat and inflammation and ultrasound appears to be an effective method to 
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assess visceral fat. If that is the case it is possible that correlating a non-invasive measure 
of visceral fat with inflammation may be used as method for diagnosis of MetS.  
   
  
Chapter 3 
Methods 
 The primary purpose of the current study was to determine the relationship 
between CRP, visceral fat, and the MetS risk factors using a modified NCEP ATPIII 
definition. This chapter provides a description of the methodology that was used to test 
the hypotheses for the current study. More specifically, this chapter provides a 
background of the participants, information on the instrumentation used, an overview of 
the procedures, and a description of the statistical analyses performed. 
Participants 
 This study was delimited to participants over the age of 40 and testing was limited 
to a maximum of 50 participants. The participants were recruited through a variety of 
methods including informational flyers, word of mouth, and referrals from in and around 
the community.  
Instrumentation  
 To conduct this study, the following variables were measured in each participant: 
height, weight, age, sex, triglyceride levels, HDL-C, fasting blood glucose levels, blood 
pressure, hip and waist circumference, visceral and subcutaneous fat, and CRP. 
Demographic information was collected through an interview with each participant. 
 Blood pressure was measured with an aneroid sphygmomanometer (ADC 
Diagnostix, Hauppage, NY) after being seated for at least five minutes. Height and 
weight were measured by a physician’s scale (Cardinal Scale Manufacturing Co., Webb 
City, MO) and stadiometer. Hip and waist circumference were measured with the use of a 
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Gulick tape measure. TG, HDL-C, fasting blood glucose, and CRP was measured through 
the use of a Cholestech LDX blood analyzer (Cholestech Corporation, Hayward, CA). 
Visceral and subcutaneous fat levels were measured with a BodyMetrix (IntelaMetrix, 
Inc., Livermore, CA) ultrasonography machine. 
Procedure 
This study was approved through the Institutional Review Board (IRB) at Eastern 
Washington University. Once the study was approved through the IRB, participants were 
recruited to participate in the study. Prior to participation, an informational meeting was 
held for all potential participants to go over informed consent. Participants were given 
24-48 hours to decide whether they wanted to participate after full disclosure of the study 
had been given.  
All testing was completed in the Human Performance Lab at Eastern Washington 
University. Blood pressure was taken after the participant was seated for at least five 
minutes. Participants’ height and weight were measured using a physician’s scale and 
stadiometer. A finger stick blood sample using a sterile lancet was performed to analyze 
TG, HDL-C, blood glucose, and CRP. TG, HDL-C, and blood glucose were measured in 
one cassette (35 ml blood) and CRP was measured in a separate cassette (40 ml blood). 
The two cassettes were then placed in the Cholestech LDX Analyzer for analysis. 
Participants had their waist circumference measured through the use of a Gulick tape 
measure, which was placed at the superior portion of the iliac crest for measurement. The 
last procedure that participants went through was an ultrasound scan of their abdomen to 
assess visceral and subcutaneous fat levels. The abdomen scan was performed by placing 
the gelled wand 1 cm to the right of the umbilicus and slowly moving it three to four 
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inches towards the hip while maintaining a perpendicular position to the surface of the 
skin. The measurement depths for visceral and subcutaneous fat were not calculated by 
the machine, so they were determined by the researchers utilizing the BodyMetrix 
software. The different fat layers are not consistent throughout the body, so the depth 
varied across the scan. Because of this, two researchers agreed on the greatest depth for 
each participant.  
Data was collected on a separate data collection sheet, void of any identifiers that 
was later entered into a Microsoft Excel file before being imported into SPSS for 
analysis. Participants had the option of receiving their results from all the tests that were 
performed. Educational materials were also available for participants who wanted more 
information about their results.   
Analysis 
Statistical analysis was performed using SPSS version 20 (SPSS Inc., Chicago, 
IL).  Data was screened for outliers as well as checked for normality. Descriptive 
statistics were provided on all of the MetS risk factors and frequencies were run to 
determine the number of participants with and without the MetS. To examine the 
relationship between the MetS risk factors, visceral fat, and CRP, Pearson’s correlations 
were utilized. T-tests were also used to identify any differences between groups. Alpha 
levels were set at p ≤ .05 for all statistical tests. 
Summary 
 Using the outlined procedures and methodology, the researchers were able to 
address the primary purpose of the current study, which was to determine the relationship 
between CRP, an inflammatory marker, and MetS risk factors. Conclusions drawn from 
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the statistical analyses were used to further the understanding of the interrelationships 
between CRP and MetS risk factors (including visceral fat). 
  
Chapter 4 
Results 
Introduction 
 The purpose of this study was to determine the relationship between CRP, 
visceral fat, and the MetS risk factors.  This chapter provides a summary of the results of 
the statistical analysis described in the previous chapter. 
Descriptive Statistics 
 Forty-five participants were initially recruited for data collection. Five 
participants were excluded from analysis due to the CRP samples not reacting. Of the 
remaining forty participants, another five were excluded from the analysis due to missing 
TG values. Additionally, one participant was excluded due to having an abnormally high 
CRP value. The overall means and standard deviations for the remaining 34 participants 
included in the analysis are summarized in Table 1 as well as the means and standard 
deviations for those with and without the MetS. In this study, the NCEP ATP III 
definition of the MetS was used as previously described. Participants who were taking 
hypertension medication were considered positive for the BP risk factor, regardless of 
their measured values. Similarly, participants who were taking medication for diabetes 
were considered positive for the impaired fasting glucose risk factor, regardless of their 
measured values.  
MetS Risk Factor Distribution 
Twenty-one percent (n = 7) of our sample population had the MetS. The most 
common risk factor was increased BP (62%) while the least common was increased WC 
(6%). A similar number of participants had impaired fasting glucose (38%) compared to 
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those with elevated TG (32%). Low HDL occurred in only 18% of the participants in the 
current study.  
Table 1. Descriptive statistics of sample population (Mean ± SD) 
 
Variable 
Total 
(n = 34) 
With MetS 
(n = 7) 
Without MetS 
 (n = 27) 
 
Age 
 
57.47 ± 9.96 
 
63.29 ± 8.36 
 
55.96 ± 9.91 
 
Weight (kg) 
 
  74.77 ± 13.58 
 
  75.40 ± 12.20 
 
  76.32 ± 14.13 
 
Height (m) 
 
  1.70 ± 0.09 
 
  1.63 ± 0.08 
 
    1.71 ± 0.09* 
 
Waist Circumference (cm) 
 
  88.37 ± 11.92 
 
96.14 ± 9.58 
 
  86.35 ± 11.78 
 
Visceral Fat Depth (mm) 
 
 17.44 ± 7.16 
 
  18.81 ± 10.32 
 
17.08 ± 6.31 
 
Systolic Blood Pressure (mmHg) 
 
  116.65 ± 9.06 
 
123.71 ± 10.55 
 
114.82 ± 7.85* 
 
Diastolic Blood Pressure (mmHg) 
 
 75.88 ± 8.90 
 
  79.43 ± 12.53 
 
74.96 ± 7.75 
 
High Density Lipoproteins (mg/dL) 
 
   61.77 ± 19.44 
 
  51.14 ± 16.80 
 
64.52 ± 3.43 
 
Triglycerides (mg/dL) 
 
 102.88 ± 64.88 
 
182.43 ± 51.21 
 
82.26 ± 50.91** 
 
Blood Glucose (mg/dL) 
 
  98.82 ± 14.23 
 
116.86 ± 16.28 
 
94.15 ± 9.26** 
 
C-reactive protein (mg/L) 
 
  1.46 ± 1.11 
 
  2.71 ± 1.37 
 
  1.14 ± 0.78** 
**p < .05, **p < .01 
 
Pearson’s Correlations 
Correlations between the MetS risk factors, visceral fat, and CRP are reported in Table 2.  
Significant moderate correlations were found between CRP and TG (r = .50, p = .05). No 
other MetS risk factors were found to be significantly correlated. There was a significant, 
moderate correlation between CRP and visceral fat depth as measured by ultrasound (r = 
.34, p = .05).  There was a weak to moderate non-significant correlation between CRP 
and FG (r = .31, p = .08), CRP and WC ( r = .29, p = .10), and CRP and systolic BP (r = 
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.28, p = .11). Also, there were weak to moderate, non-significant correlations between 
visceral fat and WC and visceral fat and systolic BP (r = .31, p = .07; r = .31, p = .08).  
Table 2.  Correlations between MetS risk factors, visceral fat, and CRP 
 WC SPB DPB CRP HDL TG VF FG LDL 
WC    -         
SBP   .42*    -        
DBP  .07  .64**    -       
CRP  .29  .28  .00   -      
HDL -.12 -.05 -.34 .09    -     
TG  .40*  .42*  .29 .50** -.09   -    
VF  .31  .31  .18 .34*  .06 .12    -   
FG  .38*  .11 -.03 .31  .01 .64** -.07   -  
LDL  .14  .15  .16 .21 -.38* .32 -.10 .37 - 
*p < .05, **p < .01 
Summary 
 A significant correlation was found between CRP and visceral fat as well as 
between CRP and TG. Non-significant weak to moderate correlations were found 
between CRP and three MetS risk factors (BP, FG, and WC). There were also non-
significant, weak to moderate correlations between visceral fat and WC and visceral fat 
and systolic BP. Overall, 21% of the studied population had the MetS and BP was the 
most common MetS risk factor while WC was the least common risk factor. 
  
Chapter 5 
Discussion 
Introduction  
The primary purpose of this study was to determine the relationship between 
CRP, visceral fat, and the MetS risk factors. The following chapter discusses the results 
of the current study as they relate to the current literature.  
Summary of results 
A total of 34 participants over the age of 40 were used in the analysis. In the 
current study, 21% (n = 7) of the population had at least three risk factors, classifying 
them as having the MetS. The frequency of the MetS in this population is slightly lower 
than previously reported in the literature (23% - 35%; Malone et al., 2009).  
CRP and visceral fat 
 A significant positive correlation was found between CRP and visceral fat as 
measured through ultrasonography. These results are in accordance with previous studies 
that have identified a relationship between CRP and visceral fat (Forouhi et al., 2001; 
Lemieux et al., 2001; Park et al., 2010; Saijo et al., 2004; Stolk et al., 2003). Previous 
studies have assessed the validity and reliability of using ultrasonography to measure 
different fat compartments, but none of them included CRP measures in their 
comparisons (Gong et al., 2007; Hirooka et al., 2005; Stolk et al., 2003).  
 Although CRP and visceral fat have been shown to have a positive relationship 
the mechanism for this relationship is unclear. One suggested mechanism is related to the 
cytokines produced by adipose tissue. Both IL-6 and TNFa are secreted by adipose tissue 
as proinflammatory cytokines, which can stimulate the liver to produce larger quantities 
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of CRP (Park et al., 2010). Visceral fat has been shown to be the more metabolically 
active adipose tissue in terms of production of both IL-6 and TNFa when compared to 
subcutaneous fat (Park et al., 2010).  
Similar to previous findings in the literature, women in the current study exhibited 
significantly higher amounts of CRP compared to men (1.90 vs. 0.77 mg/L; p = 0.002; 
Park et al., 2010). Lear et al., (2003) also showed that women, independent of age, waist 
to hip ratio, smoking, and alcohol consumption, had consistently higher CRP values 
when compared to men. One possible explanation is women who have reduced amounts 
of estrogen tend to have higher amounts of visceral fat (Spangenburg, Wohlers, & 
Valencia, 2012). In the current study, the average age of women was 59.38 years old and 
the majority of women tested were post-menopausal. A potential outcome of age and 
menopausal status of women tested is reduced estrogen and increased visceral fat or 
increased fat cell size, which may contribute to the statistically higher amounts of CRP in 
women.  
In the current study, a relationship between visceral fat and the MetS risk factors 
was identified through the use of an ultrasonography tool, which found similar results of 
Stolk et al., (2003). Of further note, Stolk et al., (2003) used a clinical grade 
ultrasonography machine within a clinical setting, whereas the current study used an 
inexpensive, consumer-grade, the BodyMetrix handheld ultrasonography wand that is 
portable and compatible with most computers. Because the BodyMetrix ultrasound 
machine produced similar results as a clinical-grade ultrasound machine as well as CT 
and MRI scans, it has the potential to be used as a screening tool for those who are at risk 
of the MetS. It may also be used by individuals or professionals to assess changes in the 
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different types of fat (visceral and subcutaneous), which are known to have an influence 
on CRP levels.  
CRP and MetS risk factors 
 Associations between CRP and the components of a lipoprotein-lipid profile have 
been identified in previous literature, yet TG was the only component with a significant 
relationship in the current study (Lemieux et al., 2001). The significant relationship 
between CRP and TG values may suggest that there is a link between inflammation and 
the body’s ability to clear fat from the blood.  A potential explanation of the relationship 
between inflammation and fat clearance is the effect of the IL-6 cytokine. Approximately 
30% of circulating IL-6 stems from adipose tissue in the body (Yudkin et al., 1999). In 
addition to stimulating CRP production in the liver, IL-6 and TNFa also affect the 
activity of lipoprotein lipase, which is the protein that is responsible for the breakdown of 
lipoproteins (Lemieux et al., 2001).  
There were also weak non-significant correlations between CRP and WC, CRP 
and systolic BP, and CRP and blood glucose. These same relationships have been 
identified as significant correlations in previous studies (Ridker et al., 2002). The lack of 
significance in the current study may be attributed to the relatively small sample size 
compared to the larger, epidemiological studies in which significance was found and also 
the fact that only seven out of 34 participants had the MetS in the current study. 
Future Research Directions 
 Further research should include a larger sample size to ensure that the correlations 
persist. Also, technicians who utilize the BodyMetrix software should become 
accustomed to the process ahead of time and screen each image before moving on to the 
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next participant, as the software does not allow the users to go back and track the 
interfaces later. During data reduction, the interfaces on the ultrasound images from 
several participants were difficult to identify, which may have led to inaccurate visceral 
fat values. It may not be possible to produce images with easily identifiable interfaces, 
but the technique can be improved upon for future research.  
The validity of the BodyMetrix as compared to clinical grade ultrasound 
machines using strict protocols should be explored. It would also be beneficial to validate 
the BodyMetrix against the gold standards of CT and/or MRI scans of fat compartments. 
These validations against the gold standards of measuring the different fat compartments 
would strengthen the value of the BodyMetrix machine for use with clinical populations 
as well as in research settings.  
In order to explore a possible explanation for the relationship between CRP and 
visceral fat through ultrasonography, it would be beneficial to include TNFa and IL-6 
measurements as well. It has been proposed that these cytokines play a role in the 
development of the MetS risk factors as well as elevated levels of CRP.  
Finally, it is of future interest to determine if changes in the amounts of visceral 
fat lead to a reduction in CRP levels over time. To assess this, an exercise protocol could 
be established to target visceral fat loss and the BodyMetrix machine could be used to 
identify changes in fat levels over the course of the experiment. 
Conclusion 
 The results of the current study suggest that there is a relationship between 
visceral fat and CRP. This finding suggests that elevated levels of visceral fat plays a role 
in chronic inflammation. This relationship did not exist between WC, a crude 
35 
 
measurement of visceral fat, and CRP, suggesting that more direct measurements of 
visceral fat such as ultrasonography are more predictive of chronic inflammation. It has 
been shown that chronic inflammation increases the risk for future cardiovascular 
disease, which also gives weight to the potential use of the BodyMetrix ultrasonography 
tool to detect changes in visceral fat levels over time.  
 To add to and strengthen the results of the current study, it is necessary to conduct 
a study with a larger number of participants and to include the measurement of 
proinflammatory cytokines such as IL-6 and TNFa. Also, exploring the reliability and 
sensitivity of the BodyMetrix machine to detect changes in visceral fat over time may be 
useful in showing that the machine can be used as a preventive tool for the MetS. 
Implementing an exercise protocol targeted at visceral fat loss can help determine if a 
change in fat levels will also lead to a reduction in CRP values over time. Finally, using 
venous blood draws to assess lipid profiles, glucose, and CRP may be preferred as they 
produce more sensitive results.  
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Appendix 1: IRB Approval 
 
To: Evan Hilberg, Department of Physical Education, Health and Recreation, 
200 PEB 
From:  Sarah A.C. Keller, Chair, Institutional Review Board 
 
Date:  February 21, 2013 
 
Subject: Expedited Review of Determining the Relationship Between C-Reactive 
Protein and the Metabolic Syndrome Risk Factors (HS-4172) 
 
The Institutional Review Board for Human Subjects' Expedited Review Committee has 
reviewed your proposal to evaluate the use of handheld ultrasonography as a method in 
the measurement of visceral fat as part of an assessment of cardiovascular risk and 
compare it to the most common methods of estimating body composition (bioelectrical 
impedance analysis and three site skin folds).  
 
The Expedited Review Committee has approved your application subject to the 
conditions noted below; a signed, approved copy of your application is enclosed.  
 
Before you begin:   
 
1. We will need a copy of the recruiting flyer that you will be distributing. 
2.  Is Dr. Peterson going to be available at EWU for training of technicians and 
lifestyle counseling? 
3.  You may provide the results of your tests to the subjects if they want them but 
as a student you may not provide them your analysis of their results.  If they are to 
receive any analysis or lifestyle counseling it must be provided by a professional 
such as Drs. Peterson or Repovich or their own physician. 
4.  Is the health questionnaire you are using the Par-Q?  If not will you please 
provide us a copy of the instrument for our files. 
 
Human subjects research approval granted by the IRB is good for one year from the date 
of approval, to February 21, 2014.  If research is to continue, with no substantial changes, 
beyond that date, a renewal of IRB approval must be obtained prior to continuation of the 
project (contact OGRD for procedure).  If, subsequent to initial approval, a research 
protocol requires minor changes, the OGRD should be notified of those changes. Any 
major departures from the original proposal must be approved by the appropriate review 
process before the protocol may be altered.  A Change of Protocol application must be 
submitted to the IRB for any substantial change in the protocol.  The Director, Grant and 
Research Development, or the Chair of the IRB will determine whether or not the 
research must then be resubmitted for approval. 
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If you have additional questions please contact me at 509-359-7039; fax 509-359-2474: 
email: skeller@ewu.edu.  It would be helpful if you would refer to HS-4172 if there were 
further correspondence as we file everything under this number.  Thank you. 
 
cc: R.Galm 
 J.Kawaguchi 
 W.Repovich 
 Graduate Office 
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Appendix 2: Informed Consent 
 
 
Informed Consent Form 
"Determining the relationship between C-reactive protein and the metabolic syndrome 
risk factors" 
In partial fulfillment of Master's Thesis for Evan Hilberg 
 
Principal Investigator     Responsible Project Investigator 
Evan Hilberg      Wendy Repovich, Ph.D., FACSM 
1604 3rd Street Cheney, WA 99004   Physical Education, Health and 
Recreation Dept. 
541-760-5072      200 Physical Education Bldg. 
evanhilberg@gmail.com    Cheney, WA 99004-2476 
 
Purpose and Benefits 
Risk for metabolic and cardiovascular disease is assessed through several biometric 
measures such as body composition, glucose, cholesterol, blood markers of 
inflammation (C-Reactive Protein), blood pressure, physical activity and visceral fat. 
The purpose of this study is to determine the relationship between c-reactive protein 
and the metabolic syndrome. 
 
Procedures 
Participation in this study will require the following procedures:  
1) A questionnaire regarding current physical activity levels will be completed. 
2) Height and weight will be measured on a standard scale.  
2)  Hip and waist circumference will be measured using a measuring tape. 
3)  Blood pressure will be measured on my right arm.  
4) A finger prick will be conducted to collect 6 drops of blood for Cholesterol, C-
Reactive protein and blood glucose tests.  
5) Body fat percentage will be measured using skin folds, ultrasonography and    
bioelectrical impedance analysis as described below:  
- Skin Fold: a small fold of skin will be measured by a trained investigator at 
three sites: men- chest, abdomen and thigh and women- triceps, suprilium 
(hip) and thigh.  
- Ultrasonography: A dime-sized amount of ultrasound gel will be placed on 
each site and the scan will be performed by moving the ultrasound wand 
over the site – back and forth three or four times. The sites are the same for 
skin folds: men- chest, abdomen and thigh and women- triceps, suprilium 
(hip) and thigh. 
- Bioelectrical Impedance Analysis: A machine (similar to a scale) will be 
used to estimate body fat percentage by sending a small electrical current 
through my body.  
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7) Visceral Fat will be estimated by Ultrasonography. A dime-sized amount of 
ultrasound gel will be placed on my abdomen and the scan will be performed by 
moving the device back and forth three to four inches above the right hip.  
 
 
Risk, Stress or Discomfort 
There is a minimal risk of an allergic reaction to the ultrasound gel. Bruising can 
occur from the skin folds, ultrasonography, blood pressure readings, and finger stick. 
There is risk of an infection at the finger stick site. Body composition results may 
cause some stress for certain individuals. Lifestyle counseling will be available for my 
benefit at the time of the measurements if needed.  
 
Inquiries 
Any questions about the procedures used in this study are encouraged. If you have any 
concerns, questions, or would like more information please contact Wendy Repovich or 
Evan Hilberg prior to signing the informed consent form. We can be reached at (509)-
359-7960; wrepovich@ewu.edu and (541) 760-5072 evanhilberg@gmail.com 
respectively. 
 
Other Information 
You are requested to not engage in an alternate training program or to alter your diet 
while you are taking part in the study. If you have any concerns about your rights as a 
participant in this research or any complaints you wish to make, you may contact Ruth 
Galm, Human Protection Administrator, (509) 359-6567 or rgalm@ewu.edu. 
 
 
 
             
Signature of Principal Investigator      Date  
 
Subject Statement 
My participation in this study is completely voluntary. I am free to refuse participation 
and to stop at any point in this study. I understand the study procedures that I will 
perform, and the possible risks that go along with the testing and training. Knowing all of 
the risks and discomforts, and being allowed to ask questions that have been answered to 
my satisfaction, I consent to take part in this study. I am not waiving my legal rights by 
signing this form. I understand I will receive a signed copy of this consent form. 
 
            
   
             
Signature of Participant        Date 
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Appendix 3: Data Collection Sheet 
 
 
Date   Subject ID#   
Demographics 
Age Sex Ht (in) 
Wt 
(lbs) WaistCir HipCir BP Smoke 
                
Physical Activity Mod(min) 
Vig 
(min) 
    
Medications HyperTen Cholest Diabetes HRT Estrogen 
Yes           
No           
Clinical Values 
Time Fasted     
CRP TC HDL-C LDL-C TG FG 
            
Body 
Composition 
Skin Folds Ultrasound 
Male/Female Trial 1 Trial 2 Trial 1 
Triceps/Chest       
SupIliac/Abd       
Thigh/Thigh       
Bioeletrical Impedance Ultrasound Measurements 
BF %   BF%   
Trunk 
% VAT   
SCAT   
Total   
 
49 
 
Appendix 4: Health History Questions 
 
Family History/Medication Questions: 
• Do you have a family history of myocardial infarction, coronary 
revascularization, or sudden death? 
o before 55 years of age in father or other male first degree relative (i.e., 
brother or son) 
o before 65 years of age in mother or other female first degree relative 
(i.e., sister or daughter) 
• Are you currently on any of the following medications? 
o Hypertension 
o Diabetes 
o Cholesterol 
o Hormone replacement therapy 
o Estrogen 
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